BUZZ-Moderna falls after 2025 sales forecast cut

Shares of vaccine maker Moderna MRNA.O fall 13.6% to $36.20 premarket

Co cut its 2025 sales forecast by $1 billion, hurt by a slow launch of its respiratory syncytial virus (RSV) shot and weak demand for COVID-19 vaccines

Co expects $1.5 bln to $2.5 bln in annual revenue, lower than its prior forecast of $2.5 bln to $3.5 bln

Analysts on average were expecting annual revenue of $2.95 bln, according to data from LSEG

Co expects to end 2025 with cash and investments of about $6 billion

Up to last close, stock had fallen 61.4% in the past 12 months

(Reporting by Sneha S K)

((Sneha.SK@thomsonreuters.com;))